These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16374852)

  • 1. Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir.
    Brouwers J; Tack J; Lammert F; Augustijns P
    J Pharm Sci; 2006 Feb; 95(2):372-83. PubMed ID: 16374852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation.
    Brouwers J; Tack J; Augustijns P
    Int J Pharm; 2007 May; 336(2):302-9. PubMed ID: 17207947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability.
    Yu L; Bridgers A; Polli J; Vickers A; Long S; Roy A; Winnike R; Coffin M
    Pharm Res; 1999 Dec; 16(12):1812-7. PubMed ID: 10644067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state.
    Brouwers J; Tack J; Augustijns P
    Pharm Res; 2007 Oct; 24(10):1862-9. PubMed ID: 17443397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.
    Dufek MB; Bridges AS; Thakker DR
    Drug Metab Dispos; 2013 Sep; 41(9):1695-702. PubMed ID: 23821186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers.
    Ingels F; Beck B; Oth M; Augustijns P
    Int J Pharm; 2004 Apr; 274(1-2):221-32. PubMed ID: 15072798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids.
    Clarysse S; Brouwers J; Tack J; Annaert P; Augustijns P
    Eur J Pharm Sci; 2011 Jul; 43(4):260-9. PubMed ID: 21570465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of fasted state human intestinal fluid as apical solvent system in the Caco-2 absorption model and comparison with FaSSIF.
    Wuyts B; Riethorst D; Brouwers J; Tack J; Annaert P; Augustijns P
    Eur J Pharm Sci; 2015 Jan; 67():126-135. PubMed ID: 25433246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption barriers in the rat intestinal mucosa. 3: Effects of polyethoxylated solubilizing agents on drug permeation and metabolism.
    Mudra DR; Borchardt RT
    J Pharm Sci; 2010 Feb; 99(2):1016-27. PubMed ID: 19650119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active intestinal drug absorption and the solubility-permeability interplay.
    Porat D; Dahan A
    Int J Pharm; 2018 Feb; 537(1-2):84-93. PubMed ID: 29102702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a differential in situ perfusion method with mesenteric blood sampling in rats for intestinal drug interaction profiling.
    Brouwers J; Mols R; Annaert P; Augustijns P
    Biopharm Drug Dispos; 2010 Jul; 31(5-6):278-85. PubMed ID: 20578213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells.
    Yamashita S; Furubayashi T; Kataoka M; Sakane T; Sezaki H; Tokuda H
    Eur J Pharm Sci; 2000 May; 10(3):195-204. PubMed ID: 10767597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of fasted and fed state simulated and human intestinal fluids as solvent system in the Ussing chambers model to explore food effects on intestinal permeability.
    Wuyts B; Riethorst D; Brouwers J; Tack J; Annaert P; Augustijns P
    Int J Pharm; 2015 Jan; 478(2):736-44. PubMed ID: 25510602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies.
    Constantinides PP; Wasan KM
    J Pharm Sci; 2007 Feb; 96(2):235-48. PubMed ID: 17051593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.
    Dahan A; Amidon GL
    Mol Pharm; 2009; 6(1):19-28. PubMed ID: 19248230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biorelevant media resistant co-culture model mimicking permeability of human intestine.
    Antoine D; Pellequer Y; Tempesta C; Lorscheidt S; Kettel B; Tamaddon L; Jannin V; Demarne F; Lamprecht A; Béduneau A
    Int J Pharm; 2015 Mar; 481(1-2):27-36. PubMed ID: 25601199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo permeability experiments in excised rat intestinal tissue and in vitro solubility measurements in aspirated human intestinal fluids support age-dependent oral drug absorption.
    Annaert P; Brouwers J; Bijnens A; Lammert F; Tack J; Augustijns P
    Eur J Pharm Sci; 2010 Jan; 39(1-3):15-22. PubMed ID: 19837159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
    Buckley ST; Frank KJ; Fricker G; Brandl M
    Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new approach to predict human intestinal absorption using porcine intestinal tissue and biorelevant matrices.
    Westerhout J; van de Steeg E; Grossouw D; Zeijdner EE; Krul CA; Verwei M; Wortelboer HM
    Eur J Pharm Sci; 2014 Oct; 63():167-77. PubMed ID: 25046168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.